Tavo Biotherapeutics, Inc.

Tavo Biotherapeutics, Inc., operating as Oculo Therapy LLC, is a woman-owned small business focused on developing innovative ophthalmic products, specifically targeting glaucoma treatments. Registered in SAM.gov since February 14, 2018, the company is a for-profit corporate entity headquartered in Memphis, Tennessee. The organization specializes in advanced pharmaceutical research and development, with a particular emphasis on novel drug delivery systems and therapeutic approaches for eye-related medical conditions.

The company has received multiple federal grant awards from the National Eye Institute (NEI) under the Vision Research program, all focused on developing advanced glaucoma treatment technologies. These grants, totaling over $1 million, support late-stage preclinical development of innovative intraocular pressure (IOP)-lowering formulations using pregabalin, an FDA-approved drug. Specifically, the grants have funded research on three critical aspects of glaucoma treatment: developing a novel extended-release microemulsion formulation for topical application, creating a subconjunctival biodegradable depot for drug delivery, and investigating the neuroprotective properties of their drug formulation. The research aims to address significant challenges in current glaucoma therapies, including poor patient adherence, limited drug release duration, and the need for neuroprotection against vision loss. Each grant represents a phase of scientific investigation, progressively building towards a potential breakthrough in glaucoma treatment that could provide more effective, longer-lasting, and patient-friendly therapeutic options.